DexCom Inc.
DXCMBusiness Overview
ticker: DXCM step: 01 generated: 2026-05-12 source: quick-research
DexCom Inc. (DXCM) — Business Overview
Business Description
DexCom is the global leader in continuous glucose monitoring (CGM) technology, enabling people with diabetes to track their glucose levels in real time without fingersticks. The company designs, develops, and commercializes CGM systems that wirelessly transmit glucose data to smartphones and compatible insulin delivery devices. Founded in 1999, DexCom has pioneered CGM for over 25 years and serves both Type 1 and Type 2 diabetes patients across the U.S. and international markets.
Revenue Model
DexCom generates the vast majority of its revenue from sales of CGM sensors (consumables replaced every 7–15 days) and transmitters/receivers (hardware). The business is recurring by nature — patients typically stay on CGM therapy long-term, driving predictable sensor repurchases. Revenue is recognized on product shipments to distributors and directly to patients. Insurance and pharmacy channel coverage is critical: Medicare, Medicaid, and commercial payers reimburse CGM for type 1 and insulin-using type 2 diabetics, while the OTC Stelo biosensor targets the consumer wellness and non-insulin type 2 population at out-of-pocket pricing.
Products & Services
- Dexcom G7: Flagship prescription CGM — slim, all-in-one sensor/transmitter with 10-day wear; the best-selling CGM in the U.S.
- Dexcom G7 15 Day: Extended-wear version launched late 2025 with improved accuracy and AID pump integrations (Insulet OmniPod, Beta Bionics, Tandem)
- Dexcom Stelo: OTC biosensor for non-insulin type 2 and wellness users; available on Amazon; over 200,000 app downloads since Q1 2025 launch
- Dexcom One+: International-focused offering at a more accessible price point
- Dexcom Smart Basal: FDA-cleared CGM-integrated basal insulin dosing optimizer
- AI Meal Logging: AI-powered meal logging feature in the Dexcom G7 and Stelo apps for personalized glucose impact insights
- Dexcom Academy: Professional education platform for healthcare providers (Belgium, Germany, Saudi Arabia, Netherlands, Spain)
Customer Base & Go-to-Market
DexCom's primary customer is the ~4–5 million CGM-eligible type 1 diabetes population (intensive insulin users) in the U.S., plus a fast-growing type 2 diabetes segment. Products reach patients through retail pharmacy (Walgreens, CVS), durable medical equipment (DME) distributors, and direct-to-patient channels. Stelo is sold direct-to-consumer via Amazon and dexcom.com. International sales (~40% of revenue) go through distributor partnerships and direct salesforces in key markets (Europe, Australia, Middle East). Concentration risk is low at the individual patient level, though pharmacy and DME distributors represent meaningful channel concentration.
Competitive Position
DexCom held approximately 74% of the U.S. CGM market in 2024 by unit share and is a top-two global player with mid-40% global value share. Its primary competitor is Abbott (FreeStyle Libre family), which competes on price and accessibility. DexCom's moat rests on (1) clinical accuracy leadership and deep brand trust among endocrinologists and type 1 patients, (2) ecosystem lock-in via validated automated insulin delivery (AID) integrations with all major insulin pump systems, (3) a 25-year head start in regulatory approvals and clinical data, and (4) manufacturing scale across Arizona, Malaysia, and a new Ireland facility coming online by 2027. Switching costs are meaningful given AID system pairing and clinician preference for accuracy.
Key Facts
- Founded: 1999
- Headquarters: San Diego, California
- Employees: ~9,000
- Exchange: NASDAQ
- Sector / Industry: Health Care / Medical Devices
- Market Cap: ~$25–28B
Financial Snapshot
ticker: DXCM step: 04 generated: 2026-05-12 source: quick-research
DexCom Inc. (DXCM) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue | $2.91B | $3.62B | $4.03B | +11% |
| Gross Margin | ~65% | ~63% | ~62% | -1pp |
| Operating Margin | ~11% | ~13% | ~15% | +2pp |
| Net Income | ~$200M | ~$380M | ~$470M | +24% |
| EPS (diluted) | ~$0.50 | ~$0.97 | ~$1.20 | +24% |
Note: Non-GAAP gross margin for FY2024 was ~62%; GAAP operating margin was 14.9% ($600M / $4.03B). EPS estimates are approximate GAAP figures; non-GAAP EPS was approximately $1.85–$2.00 for FY2024.
Cash Flow & Balance Sheet (FY2024)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$1.44B |
| Free Cash Flow | ~$1.08B |
| Cash & Equivalents | ~$3.0B |
| Total Debt | ~$2.4B |
FCF = Operating cash flow of $1.44B minus CapEx of ~$364M.
Key Ratios (approximate)
- P/E: ~50x (GAAP) | EV/Revenue: ~6x | FCF Yield: ~4%
- Revenue Growth (FY2024): +11% | FCF Margin: ~27%
- Non-GAAP Gross Margin: ~62% | Non-GAAP Operating Margin: ~19%
Growth Profile
DexCom has delivered strong revenue growth driven by penetration of the type 2 diabetes market, international expansion, and product upgrades from G6 → G7 → G7 15-Day. Growth accelerated from +11% in FY2024 to +16% in FY2025 ($4.66B), supported by the Stelo OTC launch and improving U.S. reimbursement coverage for non-insulin type 2 patients. The company is targeting $5.16–$5.25B in FY2026 revenue (+11–13%), with margin expansion as manufacturing scale (Ireland factory online by 2027) reduces COGS over time.
Forward Estimates
- FY2025 Actual: Revenue ~$4.66B (+16% YoY); non-GAAP operating margin ~20–21%
- FY2026 Guidance: Revenue $5.16–$5.25B (+11–13%); consensus non-GAAP EPS ~$2.20–$2.40
- Key upside lever: Medicare coverage expansion for ~12M non-insulin type 2 patients could accelerate growth to +15–20% range
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $DXCM.